Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033

Zhou, C.; Feng, S.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijtr, P.; Huang, H-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T.

Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/82104

Or use following links to share this resource in social networks: Recommend this item

Title	Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
Authors	Zhou, C. Feng, S. Ma, S. Chen, H. Ma, Z. Huang, C. Zhang, L. He, J. Wang, C. Zhou, J. Danchaivijtr, P. Huang, H-C. Vynnychenko, Ihor Oleksandrovych Wang, K. Orlandi, F. Sriuranpong, V. Li, B. Ge, J. Dang, T.
ORCID	http://orcid.org/0000-0002-2339-6509
Keywords	III study of pembrolizumab docetaxel (doce)
Type	Conference Papers
Date of Issue	2020
URI	https://essuir.sumdu.edu.ua/handle/123456789/82104
Publisher	Elsevier
License	Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International
Citation	Zhou C., Feng J., Ma S., Chen H., Ma Z., Huang C., Zhang L., He J., Wang C., Zhou J., Danchaivijtr P., Huang H-C., Vynnychenko I.O., Wang K., Orlandi F., Sriuranpong V., Li B., Ge J., Dang T. (2020). Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033. Annals of Oncology. Vol 31, (Suppl 4). S816. Abstract Book of the ESMO Virtual Congress 2020 19 – 21 September / 16 – 18 October 2020.
Abstract	In KEYNOTE-010, pembro improved OS vs doce as 2L+ therapy for advanced NSCLC with PD-L1 TPS 1% and 50%. KEYNOTE-010 did not enroll any pts from mainland China, which has high NSCLC mortality. KEYNOTE-033 (NCT02864394) evaluates pembro vs doce in pts with previously treated advanced NSCLC with PD-L1 TPS 1%, with most pts enrolled in mainland China.
Appears in Collections:	Наукові видання (НН МІ)